BSF Enterprise Plc, (BSFA) Fair Value & Analysis
Healthcare · GB · Market cap 4.9M GBX
Fair value as of: Jun 24, 2026
From 4 valuation models · updated 6 days ago
Share price −41.4% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.0066 – £5.14 · fair‑value band £0.0200 – £0.0300 · the £0.0113 price screens below the £0.0300 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
BSF Enterprise Plc, (BSFA) currently trades at £0.0113, while our model-based Fair Value estimate is £0.0300 — implying the stock looks roughly 166.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at £52.8K. It earns a return on equity of -37.7%. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BSF Enterprise Plc, reported revenue of £52.8K in FY2025 versus £0 in FY2021. Reported net income was −£1.1M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BSF Enterprise Plc, (BSFA) undervalued?
What is the fair value of BSFA?
What is the quality score of BSFA?
What is the revenue of BSF Enterprise Plc, (BSFA)?
What is the net profit margin of BSFA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.